NCT04250350

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 206 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to \<18 years weighing ≥40 kilograms) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	Lebrikizumab	Subcutaneous injection

Timeline

• Start date: 2020-02-11
• Primary completion: 2022-04-20
• Completion: 2022-06-22
• First posted: 2020-01-31
• Last updated: 2023-02-24
• Results posted: 2023-02-24

Locations

70 sites across 4 countries: United States, Australia, Canada, Poland

Regulatory

• FDA-regulated drug study